Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Autologous, CAR-T, CD19 May 05 | 2020Novartis Oncology Q1 2020 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring May 04 | 2020Dexcom/Ypsomed Partner for CGM Integration; Dexcom G6 Approved In Canada for Hospital Use; Diamyd Topline ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, SGLT2i May 01 | 2020Sanofi Bs-Aspart Receives Positive CHMP Opinion; No Update on CREDENCEPurchase Blast
$599
Posted in: Insulin Delivery Apr 30 | 2020Tandem Diabetes Care Q1 '20 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring Apr 30 | 2020Roche mySugr Pro Free During COVID-19 PandemicPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucagon, SGLT2i Apr 29 | 2020CREDENCE and Sanofi's Bs-Aspart up for CHMP Opinion; CHMP Agenda April 28-30Purchase Blast
$599
Posted in: Glucose Monitoring Apr 28 | 2020Dexcom Q1 '20 Earnings Update; Dexcom G7 CGM Delayed; Eversense MRI Safety Approval in EUPurchase Blast
$599
Posted in: DPP-IVi, SGLT2i Apr 28 | 2020Ertugliflozin Fails to Demonstrate CV Benefit; Merck and Pfizer Q1 '20 Earnings UpdatesPurchase Blast
$599
Posted in: SGLT2i Apr 27 | 2020Lexicon to Focus on Sota T1DM and Deprioritize T2DM; Lexicon Q1 '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA + Basal Apr 24 | 2020Efpeglenatide Officially Removed From Sanofi Pipeline; Sanofi Q1 '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Apr 23 | 2020Adocia Pramlintide+Insulin Positive Ph1b Topline ResultsPurchase Blast
$599
Posted in: Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucagon, Insulin Delivery, SGLT2i Apr 23 | 2020Empa T1DM Discontinued; Lilly Q1 '20 Earnings Update; AZ Initiates Farxiga COVID-19 TrialPurchase Blast
$599
Posted in: Autologous, BCMA, CAR-T Apr 23 | 2020New Ph1 Trial for Novartis’s BCMA CAR-T PHE885 Using a New Manufacturing MethodPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Apr 22 | 2020Roche Q1 '20 Earnings Update; SENS Secures $20M from a New Credit FacilityPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Apr 21 | 2020Thoughts on Lilly's "Tempo Pen" for Connected CarePurchase Blast
$599
Posted in: Allogeneic, Autologous, BCMA, CAR-T Apr 20 | 2020Janssen and Fate Collaborate to Develop iPSC-derived CAR-T and NK TherapiesPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other Apr 16 | 2020Abbott Q1 '20 Earnings Update; Provention Bio Initiates Rolling BLA for Teplizumab; Lilly Launches Additional Humalog AGs; Insulet’s COVID-19 ResponsePurchase Blast
$599
Posted in: Allogeneic, Autologous, BCMA, CAR-T Apr 16 | 2020J&J Q1 2020 Earnings UpdatePurchase Blast